Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 9/20 | 1.00 |
| ▸ | KEAP1 | Q14145 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.87 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.87 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.87 |
| ▸ | MBOAT4 | Q96T53 | 4/20 | 0.83 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.83 |
| ▸ | USP7 | Q93009 | 2/20 | 0.83 |
| ▸ | USP2 | O75604 | 1/20 | 0.83 |
| ▸ | STAT3 | P40763 | 1/20 | 0.83 |
| ▸ | CCR6 | P51684 | 1/20 | 0.74 |
| ▸ | RORC | P51449 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bardoxolone SCHEMBL14140295 | 1.00 | NOS2 (1.00) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| Bardoxolone SCHEMBL7717241 | 1.00 | NOS2 (1.00) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| Bardoxolone SCHEMBL92342 | 1.00 | NOS2 (1.00) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| Bardoxolone SCHEMBL12447454 | 1.00 | NOS2 (1.00) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| Bardoxolone SCHEMBL69892 | 1.00 | NOS2 (1.00) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| Bardoxolone SCHEMBL19236126 | 1.00 | NOS2 (1.00) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| Bardoxolone SCHEMBL24337284 | 1.00 | NOS2 (1.00) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| Bardoxolone SCHEMBL13569166 | 1.00 | NOS2 (1.00) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| Bardoxolone SCHEMBL13827463 | 1.00 | NOS2 (1.00) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 | |
| Bardoxolone SCHEMBL16248344 | 1.00 | NOS2 (1.00) | NOS2KEAP1CYP3A4CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1020 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739298-A1 | ACTIVATORS OF THE XC- SYSTEM AND/OR GPX-4 FOR TREATING CONDITIONS ASSOCIATED WITH CONE PHOTORECEPTOR DEGENERATION | SORBONNE UNIVERSITE (FR) | 2026-05-13 | — | — | EP | claimed |
| CN-117964676-B | CDDO quinoline derivative for inhibiting hypoxia inducible factor 1 alpha as well as preparation method and application thereof | 中国药科大学 | 2026-02-27 | — | — | CN | claimed |
| US-20260053768-A1 | Sustained Nitric Oxide Releasing Drug Delivery Systems | HADAYA MAHER (US) | 2026-02-26 | — | — | US | claimed |
| EP-3452041-B1 | COMPOSITIONS AND METHODS FOR ADMINISTERING PPAR-GAMMA-AGONISTS, SURFACTANT PEPTIDES AND PHOSPHOLIPIDS | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2026-01-14 | — | — | EP | claimed |
| US-20250352511-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | CHINOOK THERAPEUTICS INC (US) | 2025-11-20 | — | — | US | claimed |
| WO-2025235336-A1 | SUSTAINED NITRIC OXIDE RELEASING DRUG DELIVERY SYSTEMS | HADAYA MAHER (US) | 2025-11-13 | — | — | WO | claimed |
| EP-4642462-A1 | SYNTHETIC TRITERPENOIDS AND COMPOSITIONS THEREOF IN WEIGHT MANAGEMENT, SKELETAL MUSCLE FUNCTION, AND APPETITE SUPPRESSION | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-11-05 | — | — | EP | claimed |
| EP-4642788-A1 | CHEMICAL SYNTHESIS METHODS AND CDDO/CDDO-EA PREPARATIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-11-05 | — | — | EP | claimed |
| EP-4580612-A1 | USE OF NRF2 ACTIVATORS FOR THE TREATMENT OF CEREBRAL SMALL VESSEL DISEASE | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-07-09 | — | — | EP | claimed |
| EP-4572781-A2 | SYNERGISTIC INTERACTIONS FOR IMPROVED CANCER TREATMENT | The United States of America, as Represented By the Secretary, Department of Health and Human Services (US) | 2025-06-25 | — | — | EP | claimed |
| CN-114591418-A | Threonine 166 th phosphorylation modification of PPAR gamma protein and application thereof | 南京大学 | 2022-06-07 | — | — | CN | claimed |
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-05-19 | — | — | US | claimed |
| CN-114097807-A | Application of bardoxolone compound in resisting agricultural pathogenic fungi | 兰州大学 | 2022-03-01 | — | — | CN | claimed |
| CN-114106079-A | CDDO borate ester prodrug and preparation method and medical application thereof | 中国药科大学 | 2022-03-01 | — | — | CN | claimed |
| EP-3956342-A1 | METHODS AND COMPOSITIONS FOR INHIBITING THE NLRP3 INFLAMMASOME AND/OR LON PROTEASE | Triterpenoid Therapeutics, Inc. (US) | 2022-02-23 | — | — | EP | claimed |
| WO-2021062202-A1 | METHODS FOR DEPLETION OF DELETERIOUS MITOCHONDRIAL GENOMES | UNIVERSITY OF MASSACHUSETTS (US) | 2021-04-01 | — | — | WO | claimed |
| US-20210085763-A1 | Modulation of Oxidative Stress and Amino Acid Metabolism for the Treatment or Prevention of Diseases and Disorders | NEW YORK UNIVERSITY | 2021-03-25 | — | — | US | claimed |
| EP-2991621-B1 | TWO-LAYER OCULAR IMPLANT | RETINA FOUND OF THE SOUTHWEST (US) | 2020-12-09 | — | — | EP | claimed |
| US-20170231967-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | VTV THERAPEUTICS LLC | 2017-08-17 | — | — | US | claimed |
| US-20170056373-A1 | GHRELIN O-ACYLTRANSFERASE INHIBITORS | SYRACUSE UNIVERSITY (US) | 2017-03-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GLS, ATP6V1B1, PDXK | NOS2 2058/4885KEAP1 1108/4885CYP3A4 353/4885 |
| US-20260053768-A1 | Sustained Nitric Oxide Releasing Drug Delivery Systems | NOS2, NOS1, NOS3 | NOS2 1/4885KEAP1 723/4885CYP3A4 235/4885 |
| US-20170231967-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | BACH1, KEAP1, NFE2L2 | NOS2 1063/4885KEAP1 2/4885CYP3A4 4043/4885 |
| US-20250352511-A1 | METHODS OF TREATING FOCAL SEGMENTAL GLOMERULOSCLEROSIS WITH ATRASENTAN | REN, AGT, FRS2 | NOS2 2215/4885KEAP1 1217/4885CYP3A4 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.